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Abstract: Background and aims: Long-term statin use increases survival. 
However, the adherence and persistence with statin use is challenging and 
this influences the success of statin treatment. Our aim was to explore 
if monthly vitamin D supplementation (100,000-IU) improves the adherence 
to, and persistence with, long-term statin use in older adults. 
 
Methods: A secondary analysis of a trial comparing data on dispensed 
statin prescriptions, between participants allocated to vitamin D 
supplementation or placebo, for those taking statin therapy. Primary 
outcomes were defined as adherence (proportion of days covered by 
prescriptions ≥80%) and persistence (non-discontinuation of the statin 
therapy following an allowed 30 days gap between refills) with all 
statins over a 24-month measurement period of statin therapy. Secondary 
outcomes were defined as adherence and persistence at other measurement 
periods for all types of statins and for individual statins. 
 
Results: Overall, 2494 participants were on long-term statins at follow-
up (vitamin D=1243, placebo=1251). Compared with placebo, monthly vitamin 
D supplementation did not improve the proportion with adherence (risk 
ratio: 1.01, p=0.62), but improved the persistence probability of taking 
all statins after 24 months (hazard ratio: 1.15, p=0.02). In further 
analyses, significant differences were observed in the adherence to 
simvastatin, the first-line statin therapy. 
 
Conclusions: Monthly vitamin D supplementation improved persistence with 
taking statins over a 24-month measurement period in older adults on 
long-term statin therapy, especially for participants on simvastatin. The 
role of vitamin D supplementation as an adjunct therapy for patients on 
long-term statins merits further investigation. 
 
 
  
 Long-term use of statins lowers cholesterol and prevents cardiovascular disease  
 Adherence to taking statins is compromised by adverse-effects such as myalgia 
 Adherence and persistence to takin statins was assessed in a vitamin D trial 
 Monthly vitamin D3 supplementation improved persistence in taking statins 
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Abstract 
 
Background and aims: Long-term statin use increases survival. However, the adherence and 
persistence with statin use is challenging and this influences the success of statin treatment. Our aim 
was to explore if monthly vitamin D supplementation (100,000-IU) improves the adherence to, and 
persistence with, long-term statin use in older adults. 
 
Methods: A secondary analysis of a trial comparing data on dispensed statin prescriptions, between 
participants allocated to vitamin D supplementation or placebo, for those taking statin therapy. 
Primary outcomes were defined as adherence (proportion of days covered by prescriptions ≥80%) and 
persistence (non-discontinuation of the statin therapy following an allowed 30 days gap between 
refills) with all statins over a 24-month measurement period of statin therapy. Secondary outcomes 
were defined as adherence and persistence at other measurement periods for all types of statins and 
for individual statins. 
 
Results: Overall, 2494 participants were on long-term statins at follow-up (vitamin D=1243, 
placebo=1251). Compared with placebo, monthly vitamin D supplementation did not improve the 
proportion with adherence (risk ratio: 1.01, p=0.62), but improved the persistence probability of 
taking all statins after 24 months (hazard ratio: 1.15, p=0.02). In further analyses, significant 
differences were observed in the adherence to simvastatin, the first-line statin therapy. 
 
Conclusions: Monthly vitamin D supplementation improved persistence with taking statins over a 24-
month measurement period in older adults on long-term statin therapy, especially for participants on 
simvastatin. The role of vitamin D supplementation as an adjunct therapy for patients on long-term 
statins merits further investigation. 
 
Keywords: Vitamin D, statin, adherence, persistence  
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Introduction 
 
Meta-analyses of clinical trials indicate that long-term statin utilization (3-hydroxy-3-methylglutaryl-
coenzyme A reductase inhibitors) safely and significantly reduces the risk of ischemic heart disease, 
stroke, and all-cause mortality [1-3]. Based on the latest cholesterol guidelines of AHA-ACC 
(American Heart Association and the American College of Cardiology), nearly 50% of Americans 
aged 40-75 years are eligible for statin therapy [4]. However, observational studies demonstrate 
significant challenges with both long-term adherence (proportion of days covered (PDC) by 
prescriptions ≥80%) and persistence (non-discontinuation of the statin therapy with a specified gap 
between refills) with taking statin therapy. For example, one-year adherence to statins ranges from 
33% to 85% [5-7], which probably influences the effectiveness of statins in disease prevention [8-10]. 
Therefore, improving adherence to and persistence with taking statins has a potential clinical benefit 
for millions of patients. 
 
Adherence and persistence with taking medications, in general, can be influenced by barriers acting at 
a number of levels. These barriers include those in the individual patient (e.g. side effects, 
forgetfulness), the physician (e.g. not following guidelines, poor physician-patient communication), 
and the health care system (e.g. cost, insurance status) [11]. One of the principal reasons for non-
adherence and discontinuing of statins is pain-related adverse effects [12], particularly myalgia [13]. 
Although the pathophysiology of statin-related pains remains unclear, several observational studies 
have linked the problem with vitamin D deficiency [14-16], and one single group interventional study 
reported that vitamin D supplementation reverses statin intolerance caused by pain-related adverse 
effects [17]. The latter finding is supported by a meta-analysis of randomized controlled trials 
showing that vitamin D supplementation reduces pain levels in patients with chronic pain (not on 
statin therapy) [18]. Overall, the above research suggests that vitamin D supplementation might be an 
effective adjunct to improve the adherence and persistence with long-term statin therapy. 
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To our knowledge, no randomized controlled trials have explored whether vitamin D supplementation 
can improve the adherence and persistence with taking statins. To address this issue, all participants 
on long-term statin therapy in a population-based trial of vitamin D supplementation were selected to 
assess the effects of vitamin D supplementation on long-term adherence and persistence with taking 
statins. 
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Patients and methods 
 
Participants 
 
This study is a secondary analysis of participants on long-term statin therapy at follow-up evaluation 
of the Vitamin D Assessment (ViDA) study, a population-based, randomized, double-blind, placebo-
controlled trial to evaluate the effects of monthly vitamin D supplementation on cardiovascular 
disease and other health outcomes. Ethics approval was given by the New Zealand Multi-region 
Ethics Committee in Wellington in October 2010 (MEC/09/08/082/AM). Briefly, 5110 Auckland 
adults, aged 50-84 years, were recruited and randomized to taking monthly cholecalciferol (100,000-
IU) or placebo, in identical oral capsules, for up to 4 years (2011-2015). Full details of the study 
design have been published, including the requirement of written informed consent to participate [19]. 
Participants of the current sub-study were included if, after randomization, they had two or more 
prescription of statins, and had ≥90 days of statin treatment.  
 
Data collection 
 
Demographic data of eligible participants were collected at the baseline interview between 2011 and 
2012 [19]. This also included measurement, in light clothing without shoes, of height to the nearest 
0.1 cm, and weight to the nearest 0.1 kg, from which body mass index (BMI) was calculated (kg/m
2
). 
As well, a non-fasting blood sample was collected and stored at −80°C for later measurement of 
serum total cholesterol and high-density lipoprotein cholesterol levels by an Advia 2400 analyzer 
(Siemens Healthcare Diagnostics), and 25-hydroxyvitamin D (25(OH)D) by liquid chromatography–
tandem mass spectrometry (ABSciex API 4000) in a local laboratory participating in the Vitamin D 
External Quality Assessment Scheme program (www.deqas.org). Season-adjusted (deseasonalized) 
25(OH)D values were estimated for each participant from a sinusoidal model with parameters derived 
from baseline 25(OH)D values from all participants in the main ViDA study [20]. 
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Randomization 
 
Participants were randomized if they returned this questionnaire within four weeks, confirmed they 
took the study capsule, and their blood serum calcium concentration was ≤2.50 mmol/L. The 
randomization list was generated by a statistician who was not involved in outcome measures, by 
strata of 5-year age groups and ethnic categories, within randomly assigned blocks of 8, 10, or 12. The 
randomization process was done automatically, all the investigators and participants were blinded 
until the end of study. 
 
Intervention 
 
Vitamin D3 (100,000-IU or 2.5mg) or placebo soft-gel oral capsules (Tishcon Corporation, Westbury, 
New York, USA) were mailed to participants’ homes. Two capsules were sent in the first mail after 
randomization (i.e., 200,000-IU bolus or placebo), followed by a 2.5-mg (100,000-IU) capsule of 
vitaminD3 (or placebo) taken monthly thereafter. Information on study capsule adherence (vitamin D3 
or placebo) was collected by questionnaires, which were mailed with capsules to participants’ homes 
every month (or every 4-month after November 2013) along with a pre-addressed return pre-paid 
envelope. Mean 25(OH)D levels at 6, 12, 24, and 36 months after randomization were measured in a 
randomly selected sample of 441 participants (of 515 invited) who returned regularly for blood 
sample collection (220 participants were included in this secondary analysis). 
 
Prescription data of participants were identified by linking each person’s unique National Health 
Index (NHI) number with the Pharmaceutical Claims Data Mart (Pharms DM), which includes all 
subsidized prescriptions in New Zealand, and are collected by both the Ministry of Health (MOH) and 
Pharmaceutical Management Agency (www.health.govt.nz). All prescriptions for statins were 
extracted by Anatomical Therapeutic Chemical Classification System (ATC) code (C10A and C10B) 
from 6 months before randomization to the end of the study follow-up (31 July 2015). For each statin 
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prescription, the chemical name, date of dispensing, quantity dispensed, daily dose and frequency, and 
days of supply, were used for calculating the adherence and persistence with taking statins. 
 
Outcomes 
 
All study outcomes were specified before data analysis. Adherence of statin was measured by the 
PDC, which is the preferred method of measuring medication adherence, as recommended by The 
Pharmacy Quality Alliance (PQA) [21]. PDC is calculated as the total days of supply divided by a 
specified fixed measurement period [22]. The threshold of adherence is a PDC ≥80%. Statin 
persistence was defined as non-discontinuation of the statin therapy, allowing for a specified gap 
between refills, which was selected in this study to be 30 days [23]. The measurement period of this 
study began on the index date (the first day with statin therapy after the date of randomization) and 
extended for a subsequent fixed period (e.g. 6-, 12-, 24-month) or until death, and the baseline 
measurement period was defined as 6 months before randomization. The related definitions were 
illustrated in Supplementary Figure 1. 
 
The primary outcomes were adherence and persistence with taking all types of statins for a 24-month 
measurement period after the index date. The secondary outcomes were adherence and persistence 
with taking all statins for 6- and 12-month measurement periods, and individual statins for 6-, 12- and 
24-months after the index date. Four categories of statins or statin combination are subsidized in New 
Zealand, namely simvastatin, atorvastatin, pravastatin, and ezetimibe with simvastatin. In the analysis 
of adherence and persistence with taking all statins, the four statin categories were considered as a 
single class of prescriptions in the analysis. 
 
Statistical analysis 
 
The t-test or chi-square test were used to examine differences in baseline characteristics between the 
vitamin D and placebo groups. Risk ratios (RR) and corresponding two-sided 95%CI were estimated 
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with Cochran–Mantel–Haenszel chi-square for cumulative adherence to taking statins (PDC ≥80% for 
each time period) at the 6-, 12- and 24-month time points. The Cox proportional hazards model was 
used to investigate any differences in survival (persistence) probability between the two groups 
(hazard ratio (HR)), along with Kaplan-Meier curves of survival (persistence with taking statin). 
Missing data on the number of days of taking statins were estimated by dispensed quantity, daily dose 
and refilled interval. Also, atorvastatin daily dose equivalent and total amount of atorvastatin dose 
equivalent during the follow-up were calculated in the sensitivity analyses [24]. All analyses were 
performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) and two-sided p ≤ 0.05 was 
considered statistically significant. We opted not to correct p values for our two primary outcomes, 
based on the arguments of Rothman [25]. 
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Results 
 
Study Participants 
 
The selection of participants in this sub-study, from all 5110 participants randomized into the main 
trial (collected from 2011-2012, followed up to July 2015) is shown in Figure 1. Briefly, 2648 
participants were excluded for following reasons: two participants withdrew complete consent, one 
withdrew consent to analyze pharmaceutical data, 2501 had no statin prescription, 100 had only one 
statin prescription and 12 had less than 90 days of statin treatment. Of the 2494 selected participants, 
1243 were in the vitamin D group and 1251 in the placebo group. 
 
There were no significant differences between the vitamin D and placebo groups in the participant 
characteristics at baseline (Table 1). There were approximately equal numbers of men and women, 
and similar mean age of 67 years. More than 75% of participants had been told by a doctor (question 
in baseline interview) they had high cholesterol. The deseasonalized 25(OH)D (25-hydroxyvitamin D) 
concentration was similar between two groups, with overall average of 64.9 nmol/L (SD 22.4). 
 
Of 441 randomly selected participants were agreed to return at 6, 12, 24, and 36 months after 
randomization for collection of blood samples to measure 25(OH)D levels, 220 included in this 
secondary analysis. Observed serum 25(OH)D levels during follow-up were given in Supplementary 
Table, and much higher (by > 45.0 nmol/L) in the vitamin D group compared with placebo, with 
mean (SD) 25(OH)D respectively, being: 123 (36) nmol/L and 72 (31) nmol/L at 6 months; 109 (36) 
nmol/L and 59 (28) nmol/L at 12 months; 129 (38) nmol/L and 62 (25) nmol/L at 24 months; and 133 
(41) nmol/L and 61 (29) nmol/L at 36 months. 
 
Statin use in the baseline period 
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There were 2099 (84%) participants prescribed any types of statin therapy at any time during the 
baseline measurement period (the 6 months before randomization). During this period, 1257 
participants were prescribed simvastatin, 948 atorvastatin, 9 pravastatin and 15 ezetimibe with 
simvastatin. Furthermore, among the statin users, most received simvastatin only (n=1130) or 
atorvastatin only (n=823). The proportion of statin users during the baseline measurement period was 
similar between two groups (Table 1). 
 
During the baseline measurement period (6 months before randomization), some participants (15.8%) 
selected for this analysis were not on prescribed statins because they started after randomization. 
Regardless, adherence during the 6 months prior to randomization to taking all statins and individual 
statins was similar between vitamin D and placebo groups (all statins: 84.2 vs. 83.7%, p=0.76; 
simvastatin: 77.1 vs. 77.2%, p=0.96; atorvastatin: 86.3 vs. 86.3%, p=0.97; Table 2). Furthermore, the 
persistence (survival) probability of taking all statins and individual statins also was similar between 
two groups based on the results of log-rank test (all statins: log-rank p=0.38, simvastatin: log-rank 
p=0.37, atorvastatin: log-rank p=0.53, Table 3, Figure 2, and Supplementary Figures 2-3). 
Adherence for pravastatin and ezetimibe with simvastatin was not calculated due to the small number 
of prescriptions. In addition, no significant difference was found during the baseline period in the 
average atorvastatin daily dose equivalent between vitamin D (22.5 mg) and placebo (21.9 mg) 
groups (p=0.49). 
 
Statin use in the follow-up period 
 
During the follow-up period after randomization (up to July of 2015), there were 2494 participants 
with two or more statin prescriptions, for at least 90 days of statin therapy. The median follow-up time 
of these participants was 3.3 years (range, 2.5-4.2), and most participants (78%) received more than 
two years’ treatment of statins. Out of all of those prescribed statins, 1219 subjects received 
simvastatin therapy, 1613 atorvastatin, 100 pravastatin, and 17 ezetimibe with simvastatin. Most statin 
users were dispensed one category of statin during 24 months follow-up period after index date 
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(86.7%, n=2162), with the remainder dispensed two or more categories of statins (13.3%, n=332). The 
number of participants dispensed individual statins was more than for all statins combined (Tables 2-
3) because 13.3% were prescribed more than one category of statin. There was no difference during 
24 months follow-up in the proportion who reported changing statins (taking two or more categories 
of statin) between the vitamin D and placebo groups (12.4%, and 14.1%, respectively; p=0.22). 
 
The detailed results for the adherence to taking all statins and individual statins during the follow-up 
period are reported in Table 2. There was no difference between the vitamin D and placebo groups in 
adherence to taking all types of statins over the 24-month period (after statin index date) (RR 1.01; 
95%CI: 0.97, 1.05; p=0.62). A similar result was seen in vitamin D-deficient participants (<50 
nmol/l) (n=670; RR 1.00; 95%CI: 0.91, 1.08; p=0.92) and in those taking a high atorvastatin daily 
dose equivalent (≥ 40 mg) participants (n=518; RR=1.01; 95%CI: 0.94, 1.09; p=0.74). However, for 
simvastatin, the first-line statin, adherence was significantly higher in the vitamin D group compared 
to placebo for all measurement periods: 6-month (RR 1.10; 95%CI 1.03, 1.17; p<0.01), 12-month 
(RR 1.09; 95%CI 1.00, 1.16; p=0.05), and 24-month (RR 1.09; 95%CI 1.00, 1.19; p=0.04). Other 
secondary outcomes for statin adherence were non-significant. In addition, no significant difference 
was found in the average atorvastatin daily dose equivalent between two groups over the 24-month 
period after statin index date (vitamin D group 23.7 (19.2) mg vs. placebo 23.1 (17.7) mg, p=0.12). 
Neither was there a difference in the total amount of atorvastatin dose equivalent (atorvastatin daily 
dose equivalent × days of supply) in the vitamin D group (mean 14,906 mg, SD 13,123) compared to 
the placebo group (mean 14,247 mg, SD 13,123) over a 24-month follow-up (p=0.19). 
 
The persistence (survival probability) of continuing to take all types of statins (combined), and 
individual statins, at the end of the 6-, 12-, and 24-month measurement periods, for vitamin D 
treatment and placebo groups, are reported in Table 3, Figure 2, and Supplementary Figures 2-3. 
Vitamin D supplementation significantly improved the persistence with taking all statins up to the end 
of the 24-month measurement period after the statin index date (a primary outcome), compared with 
placebo (HR 1.15; 95%CI 1.02, 1.30; p=0.02). Findings were consistent, though not statistically 
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significant in vitamin D-deficient participants (n=670, HR 1.12; 95%CI 0.89, 1.41; p=0.34) and in 
high atorvastatin daily dose equivalent (≥ 40 mg) participants (n=518, HR 1.17; 95%CI 0.87, 1.57; 
p=0.29). For individual statin categories, persistence was lower compared to all statins combined 
because some participants changed their type of statin during follow up, thereby increase the 
probability of persistence failure. However, this applied equally to both groups and the results show 
that vitamin D supplementation significantly increased the persistence with simvastatin being taken at 
the end of 6 month (HR 1.38; 95%CI 1.09, 1.75; p<0.01), and 12 months (HR 1.20; 95%CI 1.00, 
1.44; p=0.05); the finding was of borderline significant at 24 months (HR 1.15; 95%CI 0.98, 1.34; 
p=0.08). Other secondary outcomes for statin persistence were non-significant (Table 3). 
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Discussion 
 
In this secondary analysis from the randomized, double-blind, placebo-controlled ViDA study, we 
found that monthly vitamin D supplementation significantly improved the persistence with taking 
statin therapy for a 24-month measurement period, compared to placebo. We also found significant 
improvement in the persistence with taking simvastatin for a 6-month and a 12-month measurement 
period, as well as adherence to taking simvastatin for 6-, 12-, and 24-month periods. 
 
The most common reason for discontinuing cardiovascular medications is having adverse effects [12], 
which affected as many as 72% of patients in one New Zealand study [26]. Given the evidence 
linking vitamin D deficiency with statin myalgia [14-17], it is possible that vitamin D 
supplementation may increase persistence in taking statins by decreasing or preventing pain related 
side-effects. 
 
Previous studies aiming to increase adherence and persistence with taking lipid lowering medication 
mainly have used behavioral intervention approaches, such as simplification of drug regimens, 
education, intensified patient care, pharmacy-led strategies and administrative improvements [27]. 
These studies show that the improvement from these interventions in adherence to taking 
cardiovascular medications varies widely. Specifically, the adherence improvement from 
simplification of the drug regimen ranges from 5% to 35% [26, 28, 29], education improvement from 
4% to 8% [30-32], intensified patient care improvement from 2% to 24% [27], compared with control 
group. Compared with the previous research, our study shows that the absolute improvement in 
adherence and persistence with taking statins is of comparable magnitude. 
 
The absolute increase in statin persistence from vitamin D supplementation over 24 months in our 
study was +4.4%, indicating that 23 patients on statins would need to take vitamin D supplements for 
2 years to prevent 1 person stopping their statin medication. Over a longer period, which is the 
situation for most patients prescribed statins, the number needed-to-treat with vitamin D would be 
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expected to decrease, as Figure 2 shows that the experience of the vitamin D and placebo groups are 
continuing to diverge. By improving the statin adherence and persistence, vitamin D supplementation 
may provide an effective and inexpensive way to improve the effectiveness of statin therapy in the 
general population. 
 
Our study has a number of strengths. The results were based on a large, population-based, double-
blind, placebo-controlled trial and are likely to apply to patients treated in the general practice setting, 
the baseline characteristics were comparable between vitamin D and placebo groups, including the 
adherence to and persistence with taking statin at baseline (6 months prior to randomization). Other 
strengths include: the inclusion of participants on long-term statin utilization (≥90 days) - participants 
who may be the most likely to benefit from statin treatment of primary and secondary prevention; our 
use of objective electronic records to measure statin adherence; the high compliance (84%) of taking 
the study capsules during the study period [20]; and the high vitamin D dose which doubled vitamin D 
levels in the intervention group [20]. In addition, primary and secondary outcomes of this study were 
all defined before the data analysis. 
 
Our study also had several potential limitations. First, the analysis is based on information from a 
pharmaceutical database, which has details on dispensed prescriptions but we cannot be certain if 
participants took the statin medication dispensed to them. Second, adherence to statin therapy and 
persistence with statin taking were not specified outcomes in the study protocol, although these 
outcomes were defined before all of the reported analyses. Third, it is possible that participants 
included in our analysis did not include those who may have started taking statins in the past but 
stopped before entry into the study because of side effects (including myalgia). Thus, the analysis may 
have only included those people who tolerated statins. Fourth, this study had enough power for 
detecting adherence and persistence (post hoc: 87% power to detect a difference of 5% between two 
groups, assuming 60% of two-years adherence and persistence rates) of all statins between two 
groups, but it was under powered for atorvastatin (post hoc: 28% power to detect a difference of 2% 
between two groups, assuming 60% of two-years adherence and persistence rates) outcome 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
15 
 
individually. Therefore, studies with larger sample size will be needed to validate the effects of 
vitamin D effectiveness on adherence and persistence with individual statins. 
 
In conclusion, among adults on long-term statin therapy, monthly vitamin D supplementation, when 
compared with placebo, resulted in improved persistence in taking statins over two years, especially 
for these participants with simvastatin therapy. Furthermore, the benefits of vitamin D 
supplementation on the adherence to simvastatin, as the first-line statin used in New Zealand, were 
statistically significant for these participants on long-term simvastatin treatment. Together, these 
findings suggest that vitamin D supplementation could improve the adherence and persistence with 
taking statins in the general population. The role of vitamin D supplementation as an adjunct therapy 
for patients on long-term statins merits further investigation. 
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Table 1 Baseline characteristics of randomized participants with long-term statin therapy 
Variables 
Vitamin D 
(n=1243) 
Placebo 
(n=1251) 
p value 
Baseline assessment 
Age (y), mean (SD) 67.3 (8.1) 67.6 (7.9) 0.40 
Age (y), n (%) 
  
0.49 
50-59 221 (17.8) 194 (15.5)   
60-69 511 (41.1) 530 (42.4)   
70-79 418 (33.6) 435 (34.8)   
80-84 93 (7.5) 92 (7.3)   
Sex, n (%) 
  
0.61 
Male 821 (66.0) 814 (65.1)   
Female 422 (34.0) 437 (34.9)   
Ethnicity, n (%) 
  
0.83 
European/Other 991 (79.7) 1015 (81.1)   
Mäori 71 (5.7) 68 (5.5)   
Pacific 104 (8.4) 99 (7.9)   
South Asian 77 (6.2) 69 (5.5)   
BMI (Kg/m
2
) 
a
, mean (SD) 29.3 (5.2) 29.5 (5.2) 0.27 
BMI (Kg/m
2
) 
a
, n (%) 
  
0.70 
<25 211 (17.1) 200 (16.0)   
25.0-29.9 563 (45.5) 563 (45.2)   
≥30.0 462 (37.4) 483 (38.8)   
Missing 7 5   
25-hydroxyvitamin D (nmol/l), mean (SD) 65.5 (22.6) 64.3 (22.1) 0.16 
25-hydroxyvitamin D (nmol/l), n (%) 
  
0.24 
0-24.9 23 (1.8) 18 (1.4)   
25.0-49.9 295 (23.8) 334 (26.7)   
50.0-74.9 552 (44.4) 518 (41.5)   
75.0-99.9 372 (30.0) 380 (30.4)   
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Missing 1 1   
Cholesterol level, mean (SD)    
Total cholesterol (mmol/l) 4.4 (1.1) 4.5 (1.1) 0.62 
HDL-C (mmol/l) 1.3 (0.4) 1.3 (0.4) 0.95 
Total cholesterol /HDL-C ratio 3.5 (0.9) 3.6 (0.9) 0.78 
Missing 6 9  
High cholesterol (self-reported), n (%) 
  
0.33 
Yes 926 (75.4) 955 (77.1)   
No 302 (24.6) 284 (22.9)   
Missing 15 12   
Prescription data on statins 
b
 
All statin use, n (%) 1243 1251 0.45 
Yes 1053 (84.7) 1046 (83.6) 
 
No 190 (15.3) 205 (16.4) 
 
Simvastatin use, n (%) 
  
0.84 
Yes 629 (50.6) 628 (50.2)   
No 614 (49.4) 623 (49.8)   
Atorvastatin use, n (%) 
  
0.54 
Yes 480 (38.6) 468 (37.4)   
No 763 (61.4) 783 (62.6)   
Pravastatin use, n (%) 
  
0.51 
c
 
Yes 3 (0.2) 6 (0.5)   
No 1240 (99.8) 1245 (99.5)   
Ezetimibe with simvastatin use, n (%) 
  
0.07 
Yes 11 (0.9) 4 (0.3)   
No 1232 (99.1) 1247 (99.7)   
Missing data were excluded before testing group differences; n, number of participants; SD, standard deviation; 
HDL-C: high-density lipoprotein cholesterol; a. calculated as weight in kilograms divided by height in meters 
squared; b. all prescriptions at baseline measurement period (the 6 months before randomization); c. Fisher’s 
exact test was used.  
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Table 2 Comparison of adherence to taking statins (proportion of days covered by prescriptions ≥ 
80%) between vitamin D and placebo groups. 
Outcomes 
Measurement 
period 
Adherence Vitamin D Placebo 
Adherence 
Risk Ratios (95%CI), p 
All statins Baseline a No. of participants 1053 1046  
No 166 (15.8) 170 (16.3) 1.00 
Yes 887 (84.2) 876 (83.7) 1.01 (0.97, 1.04), p=0.76 
6-month No. of participants 1243 1251  
No 187 (15.0) 220 (17.6) 1.00 
Yes 1056 (85.0) 1031 (82.4) 1.03 (1.00, 1.07), p=0.09 
12-month No. of participants 1243 1251  
No 248 (20.0) 263 (21.0) 1.00 
Yes 995 (80.0) 988 (79.0) 1.01 (0.97, 1.05), p=0.51 
24-month No. of participants 1243 1251  
No 265 (21.3) 277 (22.1) 1.00 
Yes 978 (78.7) 974 (77.9) 1.01 (0.97, 1.05), p=0.62 
Simvastatin Baseline a No. of participants 629 628  
No 144 (22.9) 143 (22.8) 1.00 
Yes 485 (77.1) 485 (77.2) 1.00 (0.94, 1.06), p=0.96 
6-month No. of participants 596 623  
No 115 (19.3) 166 (26.6) 1.00 
Yes 481 (80.7) 457 (73.4) 1.10 (1.03, 1.17), p<0.01 
12-month No. of participants 596 623  
No 167 (28.0) 207 (33.2) 1.00 
Yes 429 (72.0) 416 (66.8) 1.08 (1.00, 1.16), p=0.05 
24-month No. of participants 596 623  
No 200 (33.6) 244 (39.2) 1.00 
Yes 396 (66.4) 379 (60.8) 1.09 (1.00,1.19), p=0.04 
Atorvastatin Baseline a No. of participants 480 468  
No 66 (13.7) 64 (13.7) 1.00 
Yes 414 (86.3) 404 (86.3) 1.00 (0.95, 1.05), p=0.97 
6-month No. of participants 802 811  
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No 123 (15.3) 131 (16.2) 1.00 
Yes 679 (84.7) 680 (83.8) 1.01 (0.97, 1.05), p=0.65 
12-month No. of participants 802 811  
No 170 (21.2) 170 (21.0) 1.00 
Yes 632 (78.8) 641 (79.0) 1.00 (0.95, 1.05), p=0.91 
24-month No. of participants 802 811  
No 202 (25.2) 195 (24.0) 1.00 
Yes 600 (74.3) 616 (76.0) 0.99 (0.93, 1.04), p=0.59 
a. the adherence calculation in the baseline measurement (the 6 months before randomization) only for participants on statin 
therapy; follow-up measurement period, begins on the first day with statin therapy after the date of randomization and 
extends through a fixed period; all types of statins included simvastatin, atorvastatin, pravastatin and ezetimibe with 
simvastatin; CI, confident intervals. 
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Table 3 Comparison of persistence in taking statins (allowing for 30 days grace period between 
prescriptions) between vitamin D and placebo groups. 
Outcomes 
Measurement 
 period 
Persistence Vitamin D Placebo 
Persistence 
Hazard Ratio (95%CI), p 
All statins Baseline a No. of participants 1053 1046  
No 179 (17.0) 162 (15.5) 1.00 
Yes 874 (83.0) 884 (84.5) 0.91 (0.74, 1.23), p=0.38 
6-month No. of participants 1243 1251  
No 199 (16.0) 225 (18.0) 1.00 
Yes 1044 (84.0) 1026 (82.0) 1.15 (0.95, 1.39), p=0.16 
12-month No. of participants 1243 1251  
No 347 (27.9) 392 (31.3) 1.00 
Yes 896 (72.1) 858 (68.7) 1.15 (1.00, 1.33), p=0.05 
24-month No. of participants 1243 1251  
No 493 (39.7) 552 (44.1) 1.00 
Yes 750 (60.3) 699 (55.9) 1.15 (1.02, 1.30), p=0.02 
Simvastatin Baseline a No. of participants 629 628  
No 150 (23.8) 136 (21.7) 1.00 
Yes 479 (76.2) 492 (78.3) 0.90 (0.71, 1.14), p=0.37 
6-month No. of participants 596 623  
No 117 (19.6) 163 (26.2) 1.00 
Yes 479 (80.4) 460 (73.8) 1.38 (1.09, 1.75), p<0.01 
12-month No. of participants 596 623  
No 214 (35.9) 254 (40.8) 1.00 
Yes 382 (64.1) 369 (59.2) 1.20 (1.00, 1.44), p=0.05 
24-month No. of participants 596 623  
No 294 (49.3) 333 (53.4) 1.00 
Yes 302 (50.7) 290 (46.6) 1.15 (0.98, 1.34), p=0.08 
Atorvastatin Baseline a No. of participants 480 468  
No 71 (14.8) 62 (13.3) 1.00 
Yes 409 (85.2) 406 (86.7) 0.90 (0.64, 1.26), p=0.53 
6-month No. of participants 802 811  
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No 146 (18.2) 154 (19.0) 1.00 
Yes 656 (81.8) 657 (81.0) 1.07 (0.85, 1.34), p=0.59 
12-month No. of participants 802 811  
No 253 (31.5) 286 (35.3) 1.00 
Yes 549 (68.5) 525 (64.7) 1.15 (0.97, 1.36), p=0.11 
24-month No. of participants 802 811  
No 387 (48.1) 421 (51.9) 1.00 
Yes 415 (51.8) 390 (48.1) 1.13 (0.98, 1.30), p=0.08 
a. the persistence calculation in the baseline measurement (the 6 months before randomization) only for participants on statin 
therapy; follow-up measurement period: begins on the first day with statin therapy after the date of randomization and 
extends through a fixed period; all types of statins included simvastatin, atorvastatin, pravastatin and ezetimibe with 
simvastatin; CI, confident intervals. 
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Figure legends 
 
Figure 1 CONSORT diagram for participants of this study. 
 
Figure 2 Kaplan-Meier plot of persistence with all statins during baseline and 24-month measurement 
period (after index date). 
Results of log-rank test are listed in the top right corner of each figure, number of participants at risk 
are shown on the bottom of each figure; persistence is defined as non-discontinuation of statin therapy 
within a 30 day gap between refills. 
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